TrialBritish journal of clinical pharmacology2017

Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.

Anna K Stalder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.